8 ud af 8 tidsskrifter valgt, søgeord (urin) valgt, emner højest 180 dage gamle, sorteret efter nyeste først.
88 emner vises.
51
Interim COVID-19 vaccination coverage in the EU/EEA during the 2023–24 season campaigns
ECDC
ECDC COVID-19 updates, 26.01.2024
Tilføjet 26.01.2024
This report presents an interim description of COVID-19 vaccine coverage in the European Union/European Economic Area (EU/EEA) between 1 September 2023 and January 2024.
Læs mere
52
Impact of nirsevimab prophylaxis on paediatric respiratory syncytial virus (RSV)-related hospitalisations during the initial 2023/24 season in Luxembourg
Corinna Ernst, Dritan Bejko, Leo Gaasch, Emilie Hannelas, Isaline Kahn, Charlotte Pierron, Nesrine Del Lero, Claude Schalbar, Elsa Do Carmo, Michel Kohnen, Emmanuelle Andlauer, Pauline Hublart, Silvana Masi, Isabel de la Fuente Garcia, Anne Vergison and Joël Mossong
Eurosurveillance latest updates, 26.01.2024
Tilføjet 26.01.2024
After Luxembourg introduced nirsevimab immunisation against respiratory syncytial virus (RSV), estimated neonatal coverage was 84% (1,277 doses/1,524 births) in 2023. That year, paediatric RSV-related hospitalisations, especially concerning infants
Læs mere
53
South America Dengue Spike Prompts Vaccination Drive as Bug Spray Runs Out
Medscape Infectious Diseases, 26.01.2024
Tilføjet 26.01.2024
South America is seeing a surge in cases of the mosquito-borne disease dengue during the southern hemisphere summer, prompting Brazil to roll out a novel vaccine campaign,... Reuters Health Information
Læs mere
54
Early-onset group B streptococcal infections in five Nordic countries with different prevention policies, 1995 to 2019
Verna Björklund, Harri Saxén, Olof Hertting, Emma Louise Malchau Carlsen, Steen Hoffmann, Stellan Håkansson, Valtýr Stefánsson Thors, Ásgeir Haraldsson, Anne Karin Brigtsen, Henrik Döllner, Heikki Huhtamäki, Tytti Pokka, Terhi Susanna Ruuska and Nordic Research Network for Paediatric Infectious Diseases Study Group (NORDPID)
Eurosurveillance latest updates, 19.01.2024
Tilføjet 19.01.2024
BackgroundNeonatal early-onset disease caused by group B Streptococcus (GBS) is a leading cause of infant morbidity. Intrapartum antibiotic prophylaxis (IAP) is effective in preventing early-onset GBS disease, but there is no agreement on the optimal strategy for identifying the pregnant women requiring this treatment, and both risk-based prophylaxis (RBP) and GBS screening-based prophylaxis (SBP) are used. AimThe aim of this study was to evaluate the effect of SBP as a public health intervention on the epidemiology of early-onset GBS infections. MethodsIn 2012, Finland started the universal SBP, while Denmark, Iceland, Norway and Sweden continued with RBP. We conducted an interrupted time series analysis taking 2012 as the intervention point to evaluate the impact of this intervention. The incidences of early- and late-onset GBS infections during Period I (1995–2011) and Period II (2012–2019) were collected from each national register, covering 6,605,564 live births. ResultsIn Finland, a reduction of 58% in the incidence of early-onset GBS disease, corresponding to an incidence rate ratio (IRR) of 0.42 (95% CI: 0.34–0.52), was observed after 2012. At the same time, the pooled IRR of other Nordic countries was 0.89 (95% CI: 0.80–1.0), specifically 0.89 (95% CI: 0.70–1.5) in Denmark, 0.34 (95% CI: 0.15–0.81) in Iceland, 0.72 (95% CI: 0.59–0.88) in Norway and 0.97 (95% CI: 0.85–1.1) in Sweden. ConclusionsIn this ecological study of five Nordic countries, early-onset GBS infections were approximately halved following introduction of the SBP approach as compared with RBP.
Læs mere
55
Time trends and modifiable factors of COVID-19 contact tracing coverage, Geneva, Switzerland, June 2020 to February 2022
Denis Mongin, Nils Bürgisser, the Covid-SMC Study Group and Delphine Sophie Courvoisier
Eurosurveillance latest updates, 19.01.2024
Tilføjet 19.01.2024
BackgroundContact tracing was one of the central non-pharmaceutical interventions implemented worldwide to control the spread of SARS-CoV-2, but its effectiveness depends on its ability to detect contacts. AimEvaluate the proportion of secondary infections captured by the contact tracing system in Geneva. MethodsWe analysed 166,892 concomitant infections occurring at the same given address from June 2020 until February 2022 using an extensive operational database of SARS-CoV-2 tests in Geneva. We used permutation to compare the total number of secondary infections occurring at the same address with that reported through manual contact tracing. ResultsContact tracing captured on average 41% of secondary infections, varying from 23% during epidemic peaks to 60% during low epidemic activity. People living in wealthy neighbourhoods were less likely to report contacts (odds ratio (OR): 1.6). People living in apartment buildings were also less likely to report contacts than those living in a house (OR: 1.1–3.1) depending on the SARS-CoV-2 variant, the building size and the presence of shops. This under-reporting of contacts in apartment buildings decreased during periods of mandatory wearing of face masks and restrictions on private gatherings. ConclusionContact tracing alone did not detect sufficient secondary infections to reduce the spread of SARS-CoV-2. Campaigns targeting specific populations, such as those in wealthy areas or apartment buildings, could enhance coverage. Additionally, measures like wearing face masks, improving ventilation and implementing restrictions on gatherings should also be considered to reduce infections resulting from interactions that may not be perceived as high risk.
Læs mere
56
Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023
Liliana Antunes, Clara Mazagatos, Iván Martínez-Baz, Verónica Gomez, Maria-Louise Borg, Goranka Petrović, Róisín Duffy, François E Dufrasne, Ralf Dürrwald, Mihaela Lazar, Ligita Jancoriene, Beatrix Oroszi, Petr Husa, Jennifer Howard, Aryse Melo, Francisco Pozo, Gloria Pérez-Gimeno, Jesús Castilla, Ausenda Machado, Aušra Džiugytė, Svjetlana Karabuva, Margaret Fitzgerald, Sébastien Fierens, Kristin Tolksdorf, Silvia-Odette Popovici, Auksė Mickienė, Gergő Túri, Lenka Součková, Nathalie Nicolay, Angela MC Rose and on behalf of the European Hospital Vaccine Effectiveness Group
Eurosurveillance latest updates, 19.01.2024
Tilføjet 19.01.2024
We conducted a multicentre hospital-based test-negative case–control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14–89 days post-vaccination, 15% (95% CI: −12 to 35) at 90–179 days, and lower to no effect thereafter.
Læs mere
57
Mpox Outbreak - Los Angeles County, California, May 4-August 17, 2023
Morbidity and Mortality Weekly Report (MMWR), 19.01.2024
Tilføjet 19.01.2024
This report describes an mpox outbreak in Los Angeles County, California during summer 2023.
Læs mere
58
Impact of sex and gender on post-COVID-19 syndrome, Switzerland, 2020
Caroline E Gebhard, Claudia Sütsch, Pimrapat Gebert, Bianca Gysi, Susan Bengs, Atanas Todorov, Manja Deforth, Philipp K Buehler, Alexander Meisel, Reto A Schuepbach, Annelies S Zinkernagel, Silvio D Brugger, Claudio Acevedo, Dimitri Patriki, Benedikt Wiggli, Jürg H Beer, Andrée Friedl, Raphael Twerenbold, Gabriela M Kuster, Hans Pargger, Sarah Tschudin-Sutter, Joerg C Schefold, Thibaud Spinetti, Chiara Henze, Mina Pasqualini, Dominik F Sager, Lilian Mayrhofer, Mirjam Grieder, Janna Tontsch, Fabian C Franzeck, Pedro D Wendel Garcia, Daniel A Hofmaenner, Thomas Scheier, Jan Bartussek, Ahmed Haider, Muriel Grämer, Nidaa Mikail, Alexia Rossi, Núria Zellweger, Petra Opić, Angela Portmann, Roland von Känel, Aju P Pazhenkottil, Michael Messerli, Ronny R Buechel, Philipp A Kaufmann, Valerie Treyer, Martin Siegemund, Ulrike Held, Vera Regitz-Zagrosek and Catherine Gebhard
Eurosurveillance latest updates, 12.01.2024
Tilføjet 12.01.2024
BackgroundWomen are overrepresented among individuals with post-acute sequelae of SARS-CoV-2 infection (PASC). Biological (sex) as well as sociocultural (gender) differences between women and men might account for this imbalance, yet their impact on PASC is unknown. AimWe assessed the impact of sex and gender on PASC in a Swiss population. MethodOur multicentre prospective cohort study included 2,856 (46% women, mean age 44.2 ± 16.8 years) outpatients and hospitalised patients with PCR-confirmed SARS-CoV-2 infection. ResultsAmong those who remained outpatients during their first infection, women reported persisting symptoms more often than men (40.5% vs 25.5% of men; p
Læs mere
59
Increase of respiratory illnesses among children in Beijing, China, during the autumn and winter of 2023
Cheng Gong, Fang Huang, Luodan Suo, Xuejiao Guan, Lu Kang, Hui Xie, Geng Hu, Peng Yang and Quanyi Wang
Eurosurveillance latest updates, 12.01.2024
Tilføjet 12.01.2024
In 2023, through an ongoing respiratory pathogen surveillance system, we observed from mid-September onwards, an increase of respiratory illness among children aged ≤ 15 years presenting at hospital outpatient clinics in Beijing, China. Data indicated that illness was caused by multiple pathogens, predominantly Mycoplasma pneumoniae. Seasonality, periodicity and high prevalence of resistance to macrolide (30 of 30 strains sequenced with the A2063G mutation) were important characteristics of the M. pneumoniae epidemic, which resulted in a rise in consultations at specialised paediatric hospitals.
Læs mere
60
Notes from the Field: Supply Interruptions of First- and Second-Line Oral Drugs to Treat Tuberculosis During the Previous 12 Months - California, January-March, 2023
Morbidity and Mortality Weekly Report (MMWR), 3.01.2024
Tilføjet 3.01.2024
This report describes a survey among tuberculosis (TB) programs in California to assess delays and shortages of TB drugs.
Læs mere
61
Acute respiratory infections in the EU/EEA: epidemiological update and current public health recommendations
ECDC
ECDC COVID-19 updates, 15.12.2023
Tilføjet 15.12.2023
Several viral and bacterial respiratory pathogens are expected to continue co-circulating at variable levels during the coming months, and contribute to increased morbidity and mortality during this period. This is typical of every winter season.
Læs mere
62
Acute respiratory infections in the EU/EEA: epidemiological update and current public health recommendations
ECDC
ECDC Epidemiological Update, 15.12.2023
Tilføjet 15.12.2023
Several viral and bacterial respiratory pathogens are expected to continue co-circulating at variable levels during the coming months, and contribute to increased morbidity and mortality during this period. This is typical of every winter season.
Læs mere
63
Mpox outbreak in France: epidemiological characteristics and sexual behaviour of cases aged 15 years or older, 2022
Catarina Krug, Arnaud Tarantola, Emilie Chazelle, Erica Fougère, Annie Velter, Anne Guinard, Yvan Souares, Anna Mercier, Céline François, Katia Hamdad, Laetitia Tan-Lhernould, Anita Balestier, Hana Lahbib, Nicolas Etien, Pascale Bernillon, Virginie De Lauzun, Julien Durand, Myriam Fayad, Investigation Team, Henriette De Valk, François Beck, Didier Che, Bruno Coignard, Florence Lot and Alexandra Mailles
Eurosurveillance latest updates, 15.12.2023
Tilføjet 15.12.2023
BackgroundLocally-acquired mpox cases were rarely reported outside Africa until May 2022, when locally-acquired-mpox cases occurred in various European countries. AimWe describe the mpox epidemic in France, including demographic and behavioural changes among a subset of cases, during its course. MethodsData were retrieved from the enhanced national surveillance system until 30 September 2022. Laboratory-confirmed cases tested positive for monkeypox virus or orthopoxviruses by PCR; non-laboratory-confirmed cases had clinical symptoms and an epidemiological link to a laboratory-confirmed case. A subset of ≥ 15-year-old male cases, notified until 1 August, was interviewed for epidemiological, clinical and sexual behaviour information. Association of symptom-onset month with quantitative outcomes was evaluated by t- or Wilcoxon tests, and with binary outcomes, by Pearson’s chi-squared or Fisher exact tests. ResultsA total of 4,856 mpox cases were notified, mostly in Île-de-France region (62%; 3,025/4,855). Cases aged ≥ 15 years were predominantly male (97%; 4,668/4,812), with 37 years (range: 15–81) as mean age. Between May and July, among the subset interviewed, mpox cases increased in regions other than Île-de-France, and mean age rose from 35 (range: 21–64) to 38 years (range: 16–75; p = 0.007). Proportions of cases attending men-who-have-sex-with-men (MSM) meeting venues declined from 60% (55/91) to 46% (164/359; p = 0.012); median number of sexual partners decreased from four (interquartile range (IQR): 1–10) to two (IQR: 1–4; p
Læs mere
64
Prospective 25-year surveillance of prion diseases in France, 1992 to 2016: a slow waning of epidemics and an increase in observed sporadic forms
Angéline Denouel, Jean-Philippe Brandel, Laurène Peckeu-Abboud, Danielle Seilhean, Elodie Bouaziz-Amar, Isabelle Quadrio, Jean-Baptiste Oudart, Sylvain Lehmann, Pantxika Bellecave, Jean-Louis Laplanche and Stéphane Haik
Eurosurveillance latest updates, 15.12.2023
Tilføjet 15.12.2023
BackgroundPrion diseases are rare, fatal disorders that have repeatedly raised public health concerns since the early 1990s. An active prion disease surveillance network providing national level data was implemented in France in 1992. AimWe aimed to describe the epidemiology of sporadic, genetic and infectious forms of prion diseases in France since surveillance implementation. MethodsWe included all suspected cases notified from January 1992 to December 2016, and cases who died during the period with a definite or probable prion disease diagnosis according to EuroCJD criteria. Demographic, clinical, genetic, neuropathological and biochemical data were collected. ResultsIn total, 25,676 suspected cases were notified and 2,907 were diagnosed as prion diseases, including 2,510 (86%) with sporadic Creutzfeldt–Jakob disease (sCJD), 240 (8%) genetic and 157 (6%) with infectious prion disease. Suspected cases and sCJD cases increased over time. Younger sCJD patients (≤ 50 years) showed phenotypes related to a distinct molecular subtype distribution vs those above 50 years. Compared to other European countries, France has had a higher number of cases with iatrogenic CJD after growth hormone treatment and variant CJD (vCJD) linked to bovine spongiform encephalopathy (second after the United Kingdom), but numbers slowly decreased over time. ConclusionWe observed a decrease of CJD infectious forms, demonstrating the effectiveness of measures to limit human exposure to exogenous prions. However, active surveillance is needed regarding uncertainties about future occurrences of vCJD, possible zoonotic potential of chronic wasting diseases in cervids and increasing trends of sCJD observed in France and other countries.
Læs mere
65
Impact of the COVID-19 pandemic on prevalence of highly resistant microorganisms in hospitalised patients in the Netherlands, March 2020 to August 2022
Wieke Altorf-van der Kuil, Cornelia CH Wielders, Romy D Zwittink, Sabine C de Greeff, Dave A. Dongelmans, Ed J Kuijper, Daan W Notermans, Annelot F Schoffelen and on behalf of the study collaborators ISIS-AR study group
Eurosurveillance latest updates, 15.12.2023
Tilføjet 15.12.2023
BackgroundThe COVID-19 pandemic resulted in adaptation in infection control measures, increased patient transfer, high occupancy of intensive cares, downscaling of non-urgent medical procedures and decreased travelling. AimTo gain insight in the influence of these changes on antimicrobial resistance (AMR) prevalence in the Netherlands, a country with a low AMR prevalence, we estimated changes in demographics and prevalence of six highly resistant microorganisms (HRMO) in hospitalised patients in the Netherlands during COVID-19 waves (March–June 2020, October 2020–June 2021, October 2021–May 2022 and June–August 2022) and interwaves (July–September 2020 and July–September 2021) compared with pre-COVID-19 (March 2019–February 2020). MethodsWe investigated data on routine bacteriology cultures of hospitalised patients, obtained from 37 clinical microbiological laboratories participating in the national AMR surveillance. Demographic characteristics and HRMO prevalence were calculated as proportions and rates per 10,000 hospital admissions. ResultsAlthough no significant persistent changes in HRMO prevalence were detected, some relevant non-significant patterns were recognised in intensive care units. Compared with pre-COVID-19 we found a tendency towards higher prevalence of meticillin-resistant Staphylococcus aureus during waves and lower prevalence of multidrug-resistant Pseudomonas aeruginosa during interwaves. Additionally, during the first three waves, we observed significantly higher proportions and rates of cultures with Enterococcus faecium (pooled 10% vs 6% and 240 vs 120 per 10,000 admissions) and coagulase-negative Staphylococci (pooled 21% vs 14% and 500 vs 252 per 10,000 admissions) compared with pre-COVID-19. ConclusionWe observed no substantial changes in HRMO prevalence in hospitalised patients during the COVID-19 pandemic.
Læs mere
66
QuickStats: Percentage of Women Who Smoked Cigarettes During Pregnancy, by Race and Hispanic Origin - National Vital Statistics System, United States, 2016 and 2022
Morbidity and Mortality Weekly Report (MMWR), 14.12.2023
Tilføjet 14.12.2023
This report describes the percentage of women who smoked cigarettes during pregnancy.
Læs mere
67
Notes from the Field: COVID-19 Pandemic-Related Changes in Blood Lead Screening - Chicago, Illinois, 2017-2022
Morbidity and Mortality Weekly Report (MMWR), 14.12.2023
Tilføjet 14.12.2023
This report describes decreases in blood lead level testing among young children during the COVID-19 pandemic.
Læs mere
68
Anxiety, Depression Soared in Young Adults During Pandemic
Medscape Infectious Diseases, 8.12.2023
Tilføjet 8.12.2023
More than a third of young adults living in the US during the COVID-19 pandemic experienced anxiety and/or depression, an outcome that may be related to economic or social uncertainty. Medscape Medical News
Læs mere
69
Factors associated with parental intention to vaccinate their child against influenza, Finland, February to March, 2022: a web-based survey
Idil Hussein, Simopekka Vänskä, Jonas Sivelä, Tuija Leino and Hanna Nohynek
Eurosurveillance latest updates, 8.12.2023
Tilføjet 8.12.2023
BackgroundInfluenza vaccination for children aged 6 months to 6 years is included in the national vaccination programme in Finland. Although all vaccines in the programme are free of charge, national coverage of influenza vaccination among children under 3 years and 3–6 years during 2020/21 was 43% and 35% respectively, with regional differences. AimTo assess factors underlying parental vaccination intention in order to increase influenza vaccine uptake among children. MethodsWe conducted a web-based survey among parents (n = 17,844) of randomly selected eligible children (aged 6 months–6 years) in February–March 2022 in five Finnish municipalities from regions of high and low coverage. Logistic regressions were used to determine associations between vaccination intention and e.g. sociodemographic factors, attitudes and knowledge. Linkage to the national vaccination register was used to confirm realisation of vaccination intention after the study. ResultsParticipation rate was 13% (n = 2,322 parents). Influenza knowledge, trust in official information, responding parent’s education level, adherence to the vaccination programme, number of children and changes in attitudes towards vaccination since COVID-19 were all associated with intention to vaccinate. Vaccination intention for children was 64%, and realised vaccination 51%. ConclusionDespite the low participation rate, both vaccinated and unvaccinated children were represented. Influenza vaccine uptake is not dependent on a single factor. Our results identified the need for open dialogue between parents and healthcare professionals, as the lack of vaccine being offered by healthcare professionals was the most reported reason for not vaccinating.
Læs mere
70
Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023
Federico Martinón-Torres, Susana Mirás-Carballal and Carmen Durán-Parrondo
Eurosurveillance latest updates, 8.12.2023
Tilføjet 8.12.2023
A monoclonal antibody for universal respiratory syncytial virus prophylaxis in infants has recently been licensed. We share our experiences of integrating nirsevimab into the regional immunisation programme in Galicia, Spain. After a 3-week hospital-based immunisation campaign with flexible individualised appointments and educational activities, nirsevimab uptake was 97.5% in the high-risk group, 81.4% in the catch-up group and 92.6% in infants born during the campaign. This successful implementation strategy can serve as a model and may inform other countries’ programmatic deliberations.
Læs mere
71
A cluster of autochthonous dengue transmission in the Paris region – detection, epidemiology and control measures, France, October 2023
Nelly Fournet, Nathalie Voiry, Julian Rozenberg, Clément Bassi, Caroline Cassonnet, Anaïs Karch, Guillaume Durand, Gilda Grard, Gabriela Modenesi, Stevens-Boris Lakoussan, Nicolas Tayliam, Marta Zatta, Sébastien Gallien, on behalf of the investigation team, Harold Noël, Ségolène Brichler and Arnaud Tarantola
Eurosurveillance latest updates, 8.12.2023
Tilføjet 8.12.2023
A cluster of three confirmed autochthonous dengue cases was detected in October 2023 in the Val-de-Marne department neighbouring Paris, France. This marks the northernmost transmission of dengue in Europe reported to date. The epidemiological and microbiological investigations and the vector control measures are described. This event confirms the need for early case detection and response to contain dengue in Europe, especially given the 2024 Summer Olympic and Paralympic Games, when millions of visitors will visit the Greater Paris area.
Læs mere
72
Notes from the Field: Undiagnosed Tuberculosis During Pregnancy Resulting in a Neonatal Death - United States, 2021
Morbidity and Mortality Weekly Report (MMWR), 8.12.2023
Tilføjet 8.12.2023
This report describes an infant death following a case of undiagnosed tuberculosis during pregnancy.
Læs mere
73
COVID Vaccines Likely Reversed Premature Birth Trend
Medscape Infectious Diseases, 1.12.2023
Tilføjet 1.12.2023
Researchers suggest this provides further evidence of benefit of SARS-CoV-2 vaccination before or during pregnancy. Medscape Medical News
Læs mere
74
Relative vaccine effectiveness of mRNA COVID-19 boosters in people aged at least 75 years during the spring-summer (monovalent vaccine) and autumn-winter (bivalent vaccine) booster campaigns: a prospective test negative case–control study, United Kingdom, 2022
Anastasia Chatzilena, Catherine Hyams, Rob Challen, Robin Marlow, Jade King, David Adegbite, Jane Kinney, Madeleine Clout, Nick Maskell, Jennifer Oliver, Adam Finn, Leon Danon and on behalf of The Avon CAP Research Group
Eurosurveillance latest updates, 1.12.2023
Tilføjet 1.12.2023
BackgroundUnderstanding the relative vaccine effectiveness (rVE) of new COVID-19 vaccine formulations against SARS-CoV-2 infection is a public health priority. A precise analysis of the rVE of monovalent and bivalent boosters given during the 2022 spring-summer and autumn-winter campaigns, respectively, in a defined population remains of interest. AimWe assessed rVE against hospitalisation for the spring-summer (fourth vs third monovalent mRNA vaccine doses) and autumn-winter (fifth BA.1/ancestral bivalent vs fourth monovalent mRNA vaccine dose) boosters. MethodsWe performed a prospective single-centre test-negative design case–control study in ≥ 75-year-old people hospitalised with COVID-19 or other acute respiratory disease. We conducted regression analyses controlling for age, sex, socioeconomic status, patient comorbidities, community SARS-CoV-2 prevalence, vaccine brand and time between baseline dose and hospitalisation. ResultsWe included 682 controls and 182 cases in the spring-summer booster analysis and 572 controls and 152 cases in the autumn-winter booster analysis. A monovalent mRNA COVID-19 vaccine as fourth dose showed 46.6% rVE (95% confidence interval (CI): 13.9–67.1) vs those not fully boosted. A bivalent mRNA COVID-19 vaccine as fifth dose had 46.7% rVE (95% CI: 18.0–65.1), compared with a fourth monovalent mRNA COVID-19 vaccine dose. ConclusionsBoth fourth monovalent and fifth BA.1/ancestral mRNA bivalent COVID-19 vaccine doses demonstrated benefit as a booster in older adults. Bivalent mRNA boosters offered similar protection against hospitalisation with Omicron infection to monovalent mRNA boosters given earlier in the year. These findings support immunisation programmes in several European countries that advised the use of BA.1/ancestral bivalent booster doses.
Læs mere
75
QuickStats: Age-Adjusted Percentage of Adults Aged ≥18 Years Who Received an Influenza Vaccination During the Past 12 Months, by Sex and Race and Ethnicity - National Health Interview Survey, United States, 2022
Morbidity and Mortality Weekly Report (MMWR), 1.12.2023
Tilføjet 1.12.2023
This report describes the percentage of adults who received a flu vaccine during the past 12 months.
Læs mere
76
Notes from the Field: The National Wastewater Surveillance System's Centers of Excellence Contributions to Public Health Action During the Respiratory Virus Season - Four U.S. Jurisdictions, 2022-23
Morbidity and Mortality Weekly Report (MMWR), 1.12.2023
Tilføjet 1.12.2023
This report describes how wastewater surveillance informed public health action during the 2022-23 respiratory virus season.
Læs mere
77
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021
Angela MC Rose, Nathalie Nicolay, Virginia Sandonis Martín, Clara Mazagatos, Goranka Petrović, F Annabel Niessen, Ausenda Machado, Odile Launay, Sarah Denayer, Lucie Seyler, Joaquin Baruch, Cristina Burgui, Isabela I Loghin, Lisa Domegan, Roberta Vaikutytė, Petr Husa, George Panagiotakopoulos, Nassera Aouali, Ralf Dürrwald, Jennifer Howard, Francisco Pozo, Bartolomé Sastre-Palou, Diana Nonković, Mirjam J Knol, Irina Kislaya, Liem binh Luong Nguyen, Nathalie Bossuyt, Thomas Demuyser, Aušra Džiugytė, Iván Martínez-Baz, Corneliu Popescu, Róisín Duffy, Monika Kuliešė, Lenka Součková, Stella Michelaki, Marc Simon, Janine Reiche, María Teresa Otero-Barrós, Zvjezdana Lovrić Makarić, Patricia CJL Bruijning-Verhagen, Verónica Gomez, Zineb Lesieur, Cyril Barbezange, Els Van Nedervelde, Maria-Louise Borg, Jesús Castilla, Mihaela Lazar, Joan O’Donnell, Indrė Jonikaitė, Regina Demlová, Marina Amerali, Gil Wirtz, Kristin Tolksdorf, Marta Valenciano, Sabrina Bacci, Esther Kissling, I-MOVE-COVID-19 hospital study team and VEBIS hospital study team
Eurosurveillance latest updates, 24.11.2023
Tilføjet 24.11.2023
IntroductionTwo large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021. AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients ≥ 20 years, combining data from these networks during Alpha (March–June)- and Delta (June–December)-dominant periods, 2021. MethodsForty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case–control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine ≥ 14 days before onset. ResultsWe included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the Alpha- and Delta-dominant periods, respectively. During the Alpha period, VE against hospitalisation with SARS-CoV2 for complete Comirnaty PSV was 85% (95% CI: 69–92) overall and 75% (95% CI: 42–90) in those aged ≥ 80 years. During the Delta period, among SARI patients ≥ 20 years with symptom onset ≥ 150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18–74). Among those receiving Comirnaty PSV and mRNA booster (any product) ≥ 150 days after last PSV dose, VE was 91% (95% CI: 57–98). In time-since-vaccination analysis, complete all-product PSV VE was > 90% in those with their last dose
Læs mere
78
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022
Angela MC Rose, Nathalie Nicolay, Virginia Sandonis Martín, Clara Mazagatos, Goranka Petrović, Joaquin Baruch, Sarah Denayer, Lucie Seyler, Lisa Domegan, Odile Launay, Ausenda Machado, Cristina Burgui, Roberta Vaikutyte, F Annabel Niessen, Isabela I Loghin, Petr Husa, Nassera Aouali, George Panagiotakopoulos, Kristin Tolksdorf, Judit Krisztina Horváth, Jennifer Howard, Francisco Pozo, Virtudes Gallardo, Diana Nonković, Aušra Džiugytė, Nathalie Bossuyt, Thomas Demuyser, Róisín Duffy, Liem binh Luong Nguyen, Irina Kislaya, Iván Martínez-Baz, Giedre Gefenaite, Mirjam J Knol, Corneliu Popescu, Lenka Součková, Marc Simon, Stella Michelaki, Janine Reiche, Annamária Ferenczi, Concepción Delgado-Sanz, Zvjezdana Lovrić Makarić, John Paul Cauchi, Cyril Barbezange, Els Van Nedervelde, Joan O’Donnell, Christine Durier, Raquel Guiomar, Jesús Castilla, Indrė Jonikaite, Patricia CJL Bruijning-Verhagen, Mihaela Lazar, Regina Demlová, Gil Wirtz, Marina Amerali, Ralf Dürrwald, Mihály Pál Kunstár, Esther Kissling, Sabrina Bacci, Marta Valenciano, I-MOVE-COVID-19 hospital study team and VEBIS hospital study team
Eurosurveillance latest updates, 24.11.2023
Tilføjet 24.11.2023
IntroductionThe I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period). MethodsIn both networks, 46 hospitals (13 countries) follow a similar test-negative case–control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received ≥ 14 days before symptom onset (stratifying first booster into received
Læs mere
79
Foodborne botulism outbreak involving different nationalities during the Rugby World Cup: critical role of credit card data and rapid international cooperation, France, September 2023
Laure Meurice, Laurent Filleul, Aurélie Fischer, Annie Burbaud, Gauthier Delvallez, Laure Diancourt, Sophie Belichon, Benjamin Clouzeau, Denis Malvy, Magali Oliva-Labadie, Coralie Bragança, Hendrik Wilking, Rafaela Franca, Greg Martin, Gauri Godbole, Mathieu Tourdjman and Nathalie Jourdan-Da Silva
Eurosurveillance latest updates, 24.11.2023
Tilføjet 24.11.2023
In September 2023, a severe outbreak of type B botulism with fifteen cases was linked to consumption of canned sardines at a restaurant in Bordeaux, France, during the Rugby World Cup. The cases were from seven countries. One death was recorded. Outbreak investigation using credit card data, rapid communication between health authorities of the affected countries and broad media communication allowed identification of cases and exposed persons and prevented further severe outcomes.
Læs mere
80
Notes from the Field: Diagnosis of Congenital Syphilis and Syphilis Among Females of Reproductive Age Before and During the COVID-19 Pandemic - Chicago, 2015-2022
Morbidity and Mortality Weekly Report (MMWR), 23.11.2023
Tilføjet 23.11.2023
This report describes increases in cases of congenital syphilis during the COVID-19 pandemic.
Læs mere
81
Rebound in community antibiotic consumption after the observed decrease during the COVID-19 pandemic, EU/EEA, 2022
Cèlia Ventura-Gabarró, Vivian H Leung, Vera Vlahović-Palčevski, Anna Machowska, Dominique L Monnet, Liselotte Diaz Högberg and ESAC-Net study group
Eurosurveillance latest updates, 17.11.2023
Tilføjet 17.11.2023
We observed a rebound in consumption of antibacterials for systemic use (ATC J01) in the community sector in the European Union/European Economic Area during 2021 and 2022, after an observed decrease between 2019 and 2020. The rates in 2022 returned to pre-COVID-19-pandemic levels and were exceeded in 13 countries. Although these patterns could partly be a result of changes in disease transmission during the study period, it could also reflect a lost opportunity to strengthen and reinforce prudent antibiotic use.
Læs mere
82
QuickStats: Percentage of Children and Adolescents Aged 4-17 Years Who Practiced Yoga During the Past 12 Months, by Sex and Age Group - National Health Interview Survey, United States, 2022
Morbidity and Mortality Weekly Report (MMWR), 17.11.2023
Tilføjet 17.11.2023
This report describes the percentage of children and adolescents who practiced yoga in the past 12 months.
Læs mere
83
'We Can't Be the Last in Line Again During a Pandemic'
Medscape Infectious Diseases, 14.11.2023
Tilføjet 14.11.2023
The director of the Pan American Health Organization is taking lessons learned from the pandemic to reshape the region\'s healthcare sector. Medscape Medical News
Læs mere
84
Pandemic Tied to a 50% Drop in Memory, Executive Function
Medscape Infectious Diseases, 13.11.2023
Tilføjet 13.11.2023
A 50% decline in working memory and executive function among older adults in the United Kingdom during the first year of the COVID-19 pandemic is linked to an increase in known risk factors for dementia. Medscape Medical News
Læs mere
85
What Happens if You Get Both COVID and Flu (or RSV) at Once?
Medscape Infectious Diseases, 12.11.2023
Tilføjet 12.11.2023
Despite our prevention efforts, some unlucky few may contract not just one of these viruses, but two at once or in close succession during the winter season. WebMD Health News
Læs mere
86
Declines in Influenza Vaccination Coverage Among Health Care Personnel in Acute Care Hospitals During the COVID-19 Pandemic - United States, 2017-2023
Morbidity and Mortality Weekly Report (MMWR), 9.11.2023
Tilføjet 9.11.2023
This report describes declines in influenza vaccination coverage among health care personnel working in hospitals during the COVID-19 pandemic.
Læs mere
87
Arthritis Prevalence Among Veterans - United States, 2017-2021
Morbidity and Mortality Weekly Report (MMWR), 9.11.2023
Tilføjet 9.11.2023
This report describes the number of U.S. veterans who reported being diagnosed with arthritis during 2017-2021.
Læs mere
88
Vital Signs: Missed Opportunities for Preventing Congenital Syphilis - United States, 2022
Morbidity and Mortality Weekly Report (MMWR), 7.11.2023
Tilføjet 7.11.2023
This report describes how health care providers outside of prenatal care settings can help prevent newborn syphilis through syphilis testing and treatment during pregnancy.
Læs mere